Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Liu, L ^a   Aleksandrowicz, E ^a   Fan, P ^a   Schonsiegel F ^a   Zhang, Y ^a   Sahr H ^b   Gladkich, J ^a   Mattern, J ^a   Depeweg, D ^b   Lehner, B ^b   Fellenberg, J ^b   Herr, I ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN; ANILIDE; PYRIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL INVASION; CELL ISOLATION; CHICKEN; CONTROLLED STUDY; DIFFERENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; MOUSE; MTT ASSAY; NONHUMAN; OSTEOBLAST; OSTEOCLASTOMA; PRIORITY JOURNAL; STROMA CELL; TUMOR SPHEROID; TUMORIGENIC STROMAL CELL; XENOTRANSPLANTATION; ANIMAL; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; FERTILIZATION; GIANT CELL TUMOR OF BONE; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; OOCYTE; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANILIDES; ANIMALS; CARCINOGENESIS; CELL ADHESION; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CHICKENS; FEMALE; FERTILIZATION; GIANT CELL TUMOR OF BONE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; OVUM; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; SPHEROIDS, CELLULAR; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928031288     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.440     Document Type: Article

References (47)

1. Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001; 127: 467-474.
2. Zheng MH, Robbins P, Xu J, Huang L, Wood DJ, Papadimitriou JM. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001; 16: 297-307.
3. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol 2006; 29: 96-99.
4. Alberghini M, Kliskey K, Krenacs T, Picci P, Kindblom L, Forsyth R et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010; 456: 97-103.
5. Szendroi M. Giant-cell tumour of bone. J Bone Joint Surg Br 2004; 86: 5-12.
6. Gupta R, Seethalakshmi V, Jambhekar NA, Prabhudesai S, Merchant N, Puri A et al. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 2008; 12: 239-248.
7. Santiago FR, Del Mar Castellano Garcia M, Montes JL, Garcia MR, Fernandez JM. Treatment of bone tumours by radiofrequency thermal ablation. Curr Rev Musculoskelet Med 2009; 2: 43-50.
8. Lackman RD, Khoury LD, Esmail A, Donthineni-Rao R. The treatment of sacral giant-cell tumours by serial arterial embolisation. J Bone Joint Surg Br 2002; 84: 873-877.
9. Balke M. Denosumab treatment of giant cell tumour of bone. Lancet Oncol 2013; 14: 801-802.
10. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14: 901-908.
11. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15: 640-649.
12. Burmester GR,Winchester RJ, Dimitriu-Bona A, Klein M, Steiner G, Sissons HA. Delineation of four cell types comprising the giant cell tumor of bone. Expression of Ia and monocytemacrophage lineage antigens. J Clin Invest 1983; 71: 1633-1648.
13. Goldring SR, Schiller AL, Mankin HJ, Dayer JM, Krane SM. Characterization of cells from human giant cell tumors of bone. Clin Orthop Relat Res 1986; 204: 59-75.
14. Robinson D, Segal M, Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology 2002; 70: 333-342.
15. Wulling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 2003; 34: 983-993.
16. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25: 371-379.
17. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-887.
18. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acutemyeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
20. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
21. Simeone DM. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008; 14: 5646-5648.
22. Abbott A. Cancer: the root of the problem. Nature 2006; 442: 742-743.
23. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
24. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
25. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-2227.
26. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
27. You WK, Sennino B, Williamson CW, Falcon B, Hashizume H, Yao LC et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71: 4758-4768.
28. Ryan DP. An open-label, phase II study of cabozantinib (XL184) in advanced pancreatic neuroendocrine and carcinoid tumors. Clin Trials 2011. ClinicalTrials.gov Identifier: NCT01466036. Study ID Number: 11-274.
29. US Food and Drug Administration. Cabozantinib 2013. InformationOnDrugs/ApprovedDrugs/ucm330213.htm (accessed 25 March 2013).
30. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31: 412-419.
31. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
32. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137: 1102-1113.
33. Balke M, Neumann A, Szuhai K, Agelopoulos K, August C, Gosheger G et al. A short-term in vivo model for giant cell tumor of bone. BMC Cancer 2011; 11: 241.
34. Janse EM, Jeurissen SH. Ontogeny and function of two non-lymphoid cell populations in the chicken embryo. Immunobiology 1991; 182: 472-481.
35. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-284.
36. Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013; 1830: 2481-2495.
37. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991; 78: 55-62.
38. Lin G, Liu G, Banie L, Wang G, Ning H, Lue TF et al. Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev 2011; 20: 1747-1752.
39. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70: 4602-4612.
40. Lan J, Liu X, Rong W, Wei F, Jiang L, Yu H et al. Stro-1(+) stromal cells have stem-like features in giant cell tumor of bone. J Surg Oncol 2012; 106: 826-836.
41. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004; 22: 405-414.
42. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 2014; 33: 116-128.
43. Singh S, Singh M, Mak I, Ghert M. Expressional analysis of GFP-tagged cells in an in vivo mouse model of giant cell tumor of bone. Open Orthop J 2013; 7: 109-113.
44. Fellenberg J, Lehner B, Witte D. Silencing of the UCHL1 gene in giant cell tumors of bone. Int J Cancer 2010; 127: 1804-1812.
45. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009; 58: 949-963.
46. Fellenberg J, Sahr H, Liu L, Schonsiegel F, Depeweg D, Lehner B et al. Rescue of silenced UCHL1 and IGFBP4 expression suppresses clonogenicity of giant cell tumor-derived stromal cells. Cancer Lett 2013; 336: 61-67.
47. Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C et al. Triptolide reverses hypoxia-induced EMT and stem-like features in pancreatic cancer by NF-kappa B downregulation. Int J Cancer 2014; 134: 2489-2503.